Ambee Pharmaceuticals reports weaker earnings, sets FY26 cash dividend
Bangladesh's pharmaceutical sector is seeing mixed financial signals as Ambee Pharmaceuticals posts lower earnings while maintaining a shareholder payout. The company reports a sharp drop in quarterly and annual EPS, even as cash flow per share and net asset value show some improvement.
Highlights
- Ambee Pharmaceuticals' Q1 FY27 EPS plunges 40% year on year to Tk0.30, while FY26 EPS drops 52% to Tk1.06 from Tk2.21.
- Net operating cash flow per share improves to Tk25.82 in FY26 from Tk9.06, but remains negative at Tk6.72 in Q1 FY27.
- The board approves a 10% cash dividend for FY26 with a record date of 2 December; shares close at Tk702.30 on 16 November.
Financial results and dividend timeline
As reported by The Business Standard, citing the Dhaka Stock Exchange, Ambee Pharmaceuticals' unaudited financial statements show first-quarter EPS for FY27 falls 40% year on year to Tk0.30 for July-September 2026, from Tk0.50 in the same period a year earlier.Annual profitability also weakens, with EPS for FY26 dropping 52% to Tk1.06 from Tk2.21 in FY25. Despite the earnings decline, net operating cash flow per share improves to Tk25.82 in FY26 from Tk9.06 a year earlier, while net asset value per share edges up to Tk13.53 as of 30 June 2026 from Tk13.47.
In the first quarter of FY27, net operating cash flow per share remains negative at Tk6.72, although the shortfall narrows from Tk9.28 in the corresponding period of the previous year. Net asset value per share rises further to Tk13.83 as of 30 September 2026.
The board recommends a 10% cash dividend for FY26. The record date is set for 2 December, and the annual general meeting is scheduled for 23 December at 11am on a digital platform.
Ownership structure and market position
Ambee Pharmaceuticals, established in 1976 and in commercial production since 1978, operates its factory and head office in Dhaka's Tejgaon industrial area. The company makes tablets, capsules, liquid medicines, gels and injectables for the domestic market and exports to Myanmar.Listed on the stock market in 1986, the company has paid-up capital of Tk2.40 crore. DSE data show sponsors and directors hold 77.25% of shares as of 31 October 2026, while institutional investors own 5.57% and general investors 17.18%; foreign and government investors hold none.
Institutional ownership declines from 8.37% as of 30 June 2025, while general investors' holdings increase. The shares close at Tk702.30 on the DSE on 16 November.
Earlier, we outlined Neumora Therapeutics’ Q3 2026 results, offering a broader context for corporate earnings updates.